Shots: The P-II SUSTAIN study involves assessing of crizanlizumab 2.5/5 mg/kg vs PBO in 132 SCD patients with sickle cell-related pain crises P-II SUSTAIN study results: 2-4 event/yr. (40.5% vs […]readmore
Tags : P-II SUSTAIN study